Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

The price of pharmaceuticals will likely go up soon, and generics are poised to be hit the hardest.

The wide-ranging executive order signed by Trump aims to reduce healthcare costs. It comes one day after the Trump ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. A healthcare worker fills a syringe with the ...

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

U.S. stocks edged lower on Tuesday afternoon as tariff uncertainty remained high and shares of consumer and healthcare ...

PARIS (Reuters) -Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, ...

Pfizer Inc. (PFE) is currently at $22.83, up $0.71 or 3.19% --Would be highest close since April 4, 2025, when it closed at $22.97 --On pace for largest percent increase since Dec. 17, 2024, when it ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

In a report released today, Geoff Meacham from Citi maintained a Hold rating on Pfizer (PFE – Research Report), with a price target of $23.00.

The U.S. Food and Drug Administration on Monday warned consumers and pharmacies that fake versions of Ozempic, a drug to ...